13 MSM HIV+ on HAART with LSD and estradiol levels >120 pmol/L
Subjects were randomly allocated to receive testosterone () or letrozole () for 6 weeks. Spector Sexual Desire Inventory (SSDI), Depression/Anxiety Stress Scale (DASS) were used
Desire and mean sexual acts improved in both treatment arms. Luteinizing hormone and testosterone increased in all men on letrozole
48 HIV+ males with decreased testosterone levels, libido, and sexual functioning
Multicenter randomized controlled trial. Testim gel was used by 24 men after 2 weeks using AndroGel. Brief male sexual function inventory (BMSFI) was used
Experimental group improved in 4 of 5 domains (sexual drive, erectile function, problem assessment, and sexual satisfaction) of BMSFI ()
Double-blind, placebo-controlled 6-week trial with biweekly testosterone injections, followed by 12 weeks. Clinical Global Impressions Scale (CGIS) was used
Testosterone group improved more on libido and energy than placebo group (). Parameters were kept by 18 weeks
Intervention study of 12 weeks of biweekly intramuscular injections of testosterone cypionate CGIS was used
Majority of the 19 subjects who completed the trial showed improvement of SD and other hypogonadism symptoms
Note: AndroGel is a registered trademark of Solvay Pharmaceuticals, Inc., Marietta, Georgia, USA, and Testim is a registered trademark of Auxilium Pharmaceuticals, Inc., Norristown, Pennsylvania, USA. MSM: Men who have sex with men. SD: sexual dysfunctions.